Zobrazeno 1 - 10
of 17
pro vyhledávání: '"D A Anthoney"'
Autor:
Emma J. West, Karen J. Scott, Emma Tidswell, Kaidre Bendjama, Nicolas Stojkowitz, Monika Lusky, Marta Kurzawa, Raj Prasad, Giles Toogood, Christy Ralph, D. Alan Anthoney, Alan A. Melcher, Fiona J. Collinson, Adel Samson
Publikováno v:
Cancers; Volume 14; Issue 9; Pages: 2181
Pexa-Vec is an engineered Wyeth-strain vaccinia oncolytic virus (OV), which has been tested extensively in clinical trials, demonstrating enhanced cytotoxic T cell infiltration into tumours following treatment. Favourable immune consequences to Pexa-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5a47e4c44c3476b7e8e33d29ab98aa2
https://pubmed.ncbi.nlm.nih.gov/35565310
https://pubmed.ncbi.nlm.nih.gov/35565310
Autor:
Mark R. Middleton, P S Virdee, Leena Elhussein, Martin Eatock, M Goff, Sharon Love, Anne Thomas, Stephen Falk, Joanna Moschandreas, Richard C. Turkington, D. Alan Anthoney, L Collins, Simon Lord
Publikováno v:
Thomas, A, Virdee, P S, Eatock, M, Lord, S R, Falk, S, Anthoney, D A, Turkington, R C, Goff, M, Elhussein, L, Collins, L, Love, S, Moschandreas, J & Middleton, M R 2020, ' Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma ', European Journal of Cancer, vol. 124, pp. 131-141 . https://doi.org/10.1016/j.ejca.2019.10.010
European Journal of Cancer
European Journal of Cancer
Background AZD8931 has equipotent activity against epidermal growth factor receptor, erbB2, and erbB3. Primary objectives were to determine the recommended phase II dose (RP2D) of AZD8931 + chemotherapy, and subsequently assess safety/preliminary cli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3f3f4d7b04b1b1073ec0ebfa84b2946
https://pure.qub.ac.uk/en/publications/1ea96e9e-4701-4ab7-aa91-f416c1e2f897
https://pure.qub.ac.uk/en/publications/1ea96e9e-4701-4ab7-aa91-f416c1e2f897
Autor:
Duncan I. Jodrell, Daniel H. Palmer, Sarah Halford, J. Evans, Lisa V. Hampson, Balaji Venugopal, Robert McLeod, Mirela Hategan, Natalie Cook, Helen Turner, Donna Michelle Smith, Bristi Basu, Aarthi Gopinathan, Michael Nebozhyn, D. Alan Anthoney, David A. Tuveson, William P. Steward, David Propper, Hayley Farmer-Hall
Publikováno v:
Cook, N, Basu, B, Smith, D M, Gopinathan, A, Evans, J, Steward, W P, Palmer, D, Propper, D, Venugopal, B, Hategan, M, Anthoney, D A, Hampson, L V, Nebozhyn, M, Tuveson, D, Farmer-Hall, H, Turner, H, McLeod, R, Halford, S & Jodrell, D 2018, ' A phase i trial of the c-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma ', British Journal of Cancer, vol. 118, no. 6, pp. 793-801 . https://doi.org/10.1038/bjc.2017.495
British Journal of Cancer
British Journal of Cancer
Background: The Notch pathway is frequently activated in cancer. Pathway inhibition by g-secretase inhibitors has been shown to be effective in pre-clinical models of pancreatic cancer, in combination with gemcitabine. Methods: A multi-centre, non-ra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45456c3b7d8810792b891ee0674468b1
https://doi.org/10.1038/bjc.2017.495
https://doi.org/10.1038/bjc.2017.495
Autor:
Susan C Short, Elizabeth S. Appleton, Gemma Migneco, David Taggart, Simon Thomson, Gerard J. Nuovo, Lucy F. Stead, Sergio A. Quezada, Samantha J. Turnbull, Adel Samson, Philip van Hille, Richard G. Vile, Julia V. Cockle, D. Beirne, Fiona Collinson, Fiona Errington-Mais, Karen Scott, Peter Selby, Euan S. Polson, Kevin J. Harrington, Erica B. Wilson, Heiko Wurdak, Martin Fuller, Stephen Griffin, Jill Thompson, Timothy Kottke, Hardev Pandha, Gnanamurthy Sivakumar, Chris Twelves, Ailsa Rose, Christy Ralph, Andrew Furness, Elizabeth Ilett, Robert Corns, Emma West, D. Alan Anthoney, Matthew C. Coffey, Ryan K. Mathew, Alan Melcher
Immune checkpoint inhibitors, including those targeting programmed cell death protein 1 (PD-1), are reshaping cancer therapeutic strategies. Evidence suggests, however, that tumor response and patient survival are determined by tumor programmed death
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4899fce1ad145ea879d424f0b5ba845
Autor:
Daniel Ford, Michiyasu Inatani, Keith Jones, David Propper, Roshan Agarwal, Martin Eatock, Wasat Mansoor, T.R. Jeffry Evans, D. Alan Anthoney, Masaichi Abe, Tomohisa Saito
Publikováno v:
BMC Cancer
Background TP300, a recently developed synthetic camptothecin analogue, is a highly selective topoisomerase I inhibitor. A phase I study showed good safety and tolerability. As camptothecins have proven active in oesophago-gastric adenocarcinomas, in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df47f5bb416a045af6d72591e0dafb10
http://europepmc.org/articles/PMC5057500
http://europepmc.org/articles/PMC5057500
Autor:
Angela Scaburri, Cinzia Pellizzoni, Guido Kroemer, Bernard Laffranchi, Rastilav Balheda, Christophe Massard, Jean-Charles Soria, Chris Twelves, Jean-Pierre Armand, M. A. Pacciarini, A Proctor, D. Alan Anthoney
Publikováno v:
Cell Cycle. 10:963-970
PHA-793887 is an inhibitor of multiple cyclin dependent kinases (CDK) with activity against CDK2, CDK1 and CDK4. The primary objectives of this first in man study were to determine the dose limiting toxicities (DLTs), maximum tolerated dose (MTD) and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::962c7776099d0b2f36b81d924efcbfe9
https://doi.org/10.4161/cc.10.6.15075
https://doi.org/10.4161/cc.10.6.15075
Publikováno v:
Annals of Clinical Biochemistry: International Journal of Laboratory Medicine. 44:300-307
The results for plasma 5-hydroxyindoleacetic acid (5-HIAA), whole blood serotonin and the chromogranins on three patients following their treatment for carcinoid disease with somatostatin analogues are presented. Two of the patients (a 56-year-old wo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8505e9e3e02f0bf3d74984d8c3767854
https://doi.org/10.1258/000456307780480936
https://doi.org/10.1258/000456307780480936
Autor:
Mike C. Bibby, Steve D. Shnyder, David J. Swaine, George R. Pettit, Ian G. Kirwan, Patricia A. Cooper, Paul M. Loadman, D. Alan Anthoney, John W. Lippert
Publikováno v:
Clinical Cancer Research. 10:1446-1453
Purpose: Combretastatin A4 phosphate (CA4P) and its structural analog, combretastatin A1 phosphate (CA1P), are soluble prodrugs capable of interacting with tubulin and causing rapid vascular shutdown within tumors. CA4P has completed Phase I clinical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::130a3a301a376e9bd5a3d53f8dacb56c
https://doi.org/10.1158/1078-0432.ccr-0518-03
https://doi.org/10.1158/1078-0432.ccr-0518-03
Autor:
D. A. Anthoney, S. B. Kaye
Publikováno v:
Annals of Oncology. 10:255-258
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fd26afdd70113520842c6f459a5b00a4
https://doi.org/10.1023/a:1008369614634
https://doi.org/10.1023/a:1008369614634
Autor:
Tomohisa Saito, Chris Twelves, Janet A Hartley, Donna Crawford, Masaichi Abe, Keith Jones, Iain R. Macpherson, Thomas Jeff Evans, Masanori Miwa, John M Hartley, D. Alan Anthoney, Jay D. Naik
Publikováno v:
BMC Cancer, Vol 12, Iss 1, p 536 (2012)
BMC Cancer
BMC Cancer
Background A Phase I dose escalation first in man study assessed maximum tolerated dose (MTD), dose-limiting toxicity (DLT) and recommended Phase II dose of TP300, a water soluble prodrug of the Topo-1 inhibitor TP3076, and active metabolite, TP3011.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::910700855e051c312492ecf91c882808
http://www.biomedcentral.com/1471-2407/12/536
http://www.biomedcentral.com/1471-2407/12/536